Skip to main content

Aura Biosciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

AURA$7.65-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

Three Months EndedJune 30,Six Months EndedJune 30,
2026202520262025
Operating Expenses:
Research and development$30,749$22,882$58,709$46,225
General and administrative17,3205,73124,22611,423
Total operating expenses48,06928,61382,93557,648
Total operating loss(48,069)(28,613)(82,935)(57,648)
Other income (expense):
Interest income, including amortization and accretion income2,3071,6783,4973,271
Other income (expense)154(36)155(59)
Total other income2,4611,6423,6523,212
Loss before income taxes(45,608)(26,971)(79,283)(54,436)
Income tax provision, net(29)(48)(39)(66)
Net loss$(45,637)$(27,019)$(79,322)$(54,502)
Net loss per common share—basic and diluted$(0.48)$(0.47)$(0.98)$(1.01)
Weighted average common stock outstanding—basic and diluted94,863,40058,015,71881,231,22254,092,728
Comprehensive loss:
Net loss$(45,637)$(27,019)$(79,322)$(54,502)
Other comprehensive income (loss):
Unrealized loss on marketable securities(290)(88)(368)(226)
Currency translation adjustment(173)8(200)(12)
Total other comprehensive loss(463)(80)(568)(238)
Total comprehensive loss$(46,100)$(27,099)$(79,890)$(54,740)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.